{"id":55307,"date":"2025-10-30T06:38:38","date_gmt":"2025-10-30T10:38:38","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/q3-earnings-beat-for-cigna-estee-lauder-biogen-lowers-fy-outlook-citi-raises-alphabet-target\/55307\/"},"modified":"2025-10-30T06:38:38","modified_gmt":"2025-10-30T10:38:38","slug":"q3-earnings-beat-for-cigna-estee-lauder-biogen-lowers-fy-outlook-citi-raises-alphabet-target","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/q3-earnings-beat-for-cigna-estee-lauder-biogen-lowers-fy-outlook-citi-raises-alphabet-target\/55307\/","title":{"rendered":"Q3 Earnings Beat for Cigna, Estee Lauder; Biogen Lowers FY Outlook; Citi Raises Alphabet Target"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Cigna (<a href=\"\/stock\/CI\">CI<\/a>)<\/strong> significantly surpassed Q3 2025 expectations with adjusted revenue of <strong>$69.57 billion<\/strong> and adjusted operating EPS of <strong>$7.83<\/strong>, while reaffirming its full-year adjusted operating EPS outlook.<\/li>\n<li><strong>Estee Lauder (<a href=\"\/stock\/EL\">EL<\/a>)<\/strong> reported robust Q1 2025 results, with net sales reaching <strong>$3.5 billion<\/strong> and adjusted EPS of <strong>$0.32<\/strong>, substantially beating analyst estimates.<\/li>\n<li><strong>Biogen (<a href=\"\/stock\/BIIB\">BIIB<\/a>)<\/strong> exceeded Q3 2025 product revenue estimates at <strong>$1.85 billion<\/strong> and reported <strong>$4.81<\/strong> adjusted EPS, but revised its full-year adjusted EPS guidance downward to <strong>$14.50-$15.00<\/strong>.<\/li>\n<li><strong>Citigroup (<a href=\"\/stock\/C\">C<\/a>)<\/strong> has increased its price target for <strong>Alphabet Inc. (<a href=\"\/stock\/GOOGL\">GOOGL<\/a>, <a href=\"\/stock\/GOOG\">GOOG<\/a>)<\/strong> shares to <strong>$343<\/strong> from <strong>$280<\/strong>, reflecting a positive analyst sentiment.<\/li>\n<\/ul>\n<h2>Cigna Delivers Strong Q3 Performance Amidst Dynamic Environment<\/h2>\n<p>Global health company <strong>Cigna (<a href=\"\/stock\/CI\">CI<\/a>)<\/strong> announced a strong third quarter for 2025, reporting adjusted revenues of <strong>$69.57 billion<\/strong>, outperforming analyst estimates of <strong>$67.39 billion<\/strong>. The company&#39;s adjusted operating earnings per share (EPS) reached <strong>$7.83<\/strong>, comfortably exceeding the consensus estimate of <strong>$7.64<\/strong>.<\/p>\n<p>A key driver for this performance was the Evernorth Health Services segment, which saw adjusted revenues climb to <strong>$60.39 billion<\/strong>, surpassing estimates of <strong>$58.78 billion<\/strong>. Cigna&#39;s medical care ratio improved to <strong>84.8%<\/strong>, better than the anticipated <strong>85.2%<\/strong>. The company also reaffirmed its full-year 2025 adjusted operating EPS outlook of at least <strong>$29.60<\/strong>, aligning closely with analyst expectations.<\/p>\n<h2>Estee Lauder&#39;s Q1 Exceeds Expectations<\/h2>\n<p><strong>Estee Lauder Companies Inc. (<a href=\"\/stock\/EL\">EL<\/a>)<\/strong> reported impressive fiscal first-quarter 2025 results, with net sales reaching <strong>$3.5 billion<\/strong>, significantly higher than the estimated <strong>$3.382 billion<\/strong>. The beauty giant&#39;s adjusted EPS came in at <strong>$0.32<\/strong>, well above the analyst consensus of <strong>$0.18<\/strong> to <strong>$0.19<\/strong>.<\/p>\n<p>The company&#39;s performance was bolstered by strong segment results, with Skin Care revenue hitting <strong>$1.58 billion<\/strong> against an estimated <strong>$1.56 billion<\/strong>. Makeup revenue met expectations at <strong>$1.03 billion<\/strong>. Despite a net income of <strong>$47 million<\/strong> for the quarter, <strong>Estee Lauder<\/strong> reaffirmed its fiscal year 2026 outlook, including organic net sales growth of <strong>0% to +3%<\/strong>.<\/p>\n<h2>Biogen Lowers Full-Year EPS Guidance Despite Q3 Beat<\/h2>\n<p><strong>Biogen (<a href=\"\/stock\/BIIB\">BIIB<\/a>)<\/strong> posted third-quarter 2025 revenues of <strong>$2.5 billion<\/strong> and adjusted EPS of <strong>$4.81<\/strong>, both exceeding analyst expectations. Product revenue specifically reached <strong>$1.85 billion<\/strong>, surpassing the estimated <strong>$1.78 billion<\/strong>.<\/p>\n<p>However, the pharmaceutical company revised its full-year 2025 adjusted EPS guidance downwards to a range of <strong>$14.50-$15.00<\/strong>, from a previous outlook of <strong>$15.50-$16.00<\/strong>. This updated outlook includes an anticipated <strong>$1.25 EPS impact<\/strong> stemming from development transactions.<\/p>\n<h2>Citigroup Boosts Alphabet Target Price<\/h2>\n<p><strong>Citigroup (<a href=\"\/stock\/C\">C<\/a>)<\/strong> has shown increased confidence in <strong>Alphabet Inc. (<a href=\"\/stock\/GOOGL\">GOOGL<\/a>, <a href=\"\/stock\/GOOG\">GOOG<\/a>)<\/strong>, raising its price target for the tech giant&#39;s shares to <strong>$343<\/strong> from the previous <strong>$280<\/strong>. This upward revision by the financial institution indicates a positive outlook on <strong>Alphabet&#39;s<\/strong> future performance and market valuation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Cigna (CI) significantly surpassed Q3 2025 expectations with adjusted revenue of $69.57 billion and adjusted operating EPS of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[6381,80,7013,814,7443,1807,7791,3470,8043,3768,12641,3790,3832,3886,6240],"class_list":["post-55307","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-alphabet","tag-goog","tag-biogen","tag-biib","tag-cigna","tag-earnings","tag-outlook","tag-financials","tag-q3-2025","tag-googl","tag-estee-lauder","tag-ci","tag-el","tag-eps","tag-target-price"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/55307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=55307"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/55307\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=55307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=55307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=55307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}